… ProQR Prices $90 Million Underwritten Public Offering of … and CAMBRIDGE, Mass., March 30, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR), a company dedicated … of $6.50 per share. All of the shares are being offered by ProQR. In addition, ProQR has granted the underwriters a …
… ProQR Announces R&D Day in New York on June 15 Key updates: ProQR to host an … Usher syndrome and other DEB mutations An introduction to ProQR’s novel RNA editing platform technology called Axiomer … ready to enter development,” said Daniel de Boer, CEO of ProQR. “We’re looking forward to provide an update on the …
… ProQR Announces R&D Day and Provides Update on Innovation Portfolio First … NY LEIDEN, Netherlands, Nov. 30, 2015 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … to the future of medicine,” said Daniel de Boer, CEO of ProQR. “Our innovation platform has been very efficient and …
… ProQR Appoints Naveed Shams, MD, PhD as Chief Scientific … medicine platform from David Rodman, MD, who is departing ProQR. Dr. Shams brings to ProQR deep ophthalmology, … provide strategic direction, oversight, and execution for ProQR’s research and early development efforts. This entails …
… ProQR to Present at Scientific and Investor Conferences in … be accessible from the ‘Investor Relations’ section of ProQR’s website ( www.proqr.com ) under ‘Events and Presentations’. The …
… ProQR to Present at Upcoming JMP Securities Life Sciences … will be accessible from the “Investors & Media” section of ProQR’s website ( www.proqr.com ) under “ Eve n ts ”. The archived webcast will …
